ICU MEDICAL INC/DE Q1 FY2025 earnings call

Vivek Jain walked through Q1 revenue and earnings performance, provided commentary on business segments. Brian Bonnell recapped Q1 results, discussed joint venture impact, tariffs, and financials. Highlights include revenue of $599 million, adjusted EBITDA of $99 million, adjusted EPS of $1.72. Formation of joint venture with Otsuka Pharmaceutical Factory, progress on regulatory clearances for pumps, and quality remediation efforts on MedFusion and CAD products.

Consumables segment grew 10% on a constant currency basis (9% reported). IV Systems segment grew 8% constant currency (6% reported). Vital Care segment grew 11% constant currency (10% reported). All three segments had good year-over-year growth.

Full-year 2025 guidance was confirmed with no changes related to the JV transaction. Anticipated direct expense from tariffs in FY 2025 is $25 to $30 million, with favorable currency impact offsetting almost half, but $5 to $10 million unmitigated residual impact from tariffs. Original FY 2025 guidance is still appropriate but may be at the low end if additional offsets aren't identified.

Impacts from recently implemented tariffs, evolving global trade landscape, macroeconomic knock-on effects including foreign currency fluctuations and inflation, regulatory risks such as the FDA warning letter and need for new 510(k)s on MedFusion and CAD products.

Q: Can you flesh out the reacceleration or drivers in consumables?

A: Oncology growth, renal markets, home infusion/chronic care markets, and GPO activity and pricing changes.

Q: Are we seeing more contribution from Duo in infusion systems?

A: Very few Duo installs to date, expected more in the second half of the year.

Q: Update on Mexico tariff impact?

A: USMCA exemption mitigates significant percentage of tariff exposure from Mexico, with some improvement in mitigation actions.

Q: Any signs of CapEx slowing due to tariffs?

A: No meaningful change seen in capital environment, things that need to get done get done.